Literature DB >> 27096691

Non-Alcoholic Steatohepatitis: Clinical and Translational Research.

Manuela G Neuman1, Mihai Voiculescu, Radu M Nanau, Yaakov Maor, Ehud Melzer, Lawrence B Cohen, Mihai Opris, Stephen Malnick.   

Abstract

UNLABELLED: The present review includes translational and clinical research that characterize non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Clinical and experimental evidence led to the recognition of the key toxic role played by lipotoxicity in the pathogenesis of NAFLD. The current understanding of lipotoxicity suggests that organ injury is initiated by the generation of oxidative metabolites and the translocation of gut-derived endotoxin. These processes lead to cellular injury and stimulation of the inflammatory responses mediated through a variety of molecules. The injury progresses through impairment of tissue regeneration and extracellular matrix turnover, leading to fibrogenesis and cirrhosis. Several cell types are involved in this process, predominantly stellate cells, macrophages and parenchymal cells. In response to inflammation, cytokines activate many signaling cascades that regulate fibrogenesis. This examination brings together research focusing on the underlying mechanisms of injury. It highlights the various processes and molecules that are likely involved in inflammation, immune modulation, and fibrogenesis in the liver. We searched electronic databases (Medline, Embase) for this review. This integrative work investigates different aspects of liver damage and possible repair. We aim to (1) determine the immuno-pathology of liver damage due to steatosis, (2) suggest diagnostic markers of NASH, (3) examine the role of behaviour in the development of NASH, and (4) develop common tools to study steatosis-induced effects in clinical studies. Special accent is put on co-morbidities with renal and neuropsychological disorders. Moreover, we review the evidence in literature on the role of moderate alcohol consumption in individuals that present NAFLD/NASH. KEY WORDS: behavior, diet, imaging, non-alcoholic fatty liver, nonalcoholic steatohepatitis, laboratory markers.This article is open to POST-PUBLICATION REVIEW. Registered readers (see "For Readers") may comment by clicking on ABSTRACT on the issue's contents page.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27096691     DOI: 10.18433/J3F61F

Source DB:  PubMed          Journal:  J Pharm Pharm Sci        ISSN: 1482-1826            Impact factor:   2.327


  4 in total

Review 1.  Lipocalin 2 (LCN2) Expression in Hepatic Malfunction and Therapy.

Authors:  Anastasia Asimakopoulou; Sabine Weiskirchen; Ralf Weiskirchen
Journal:  Front Physiol       Date:  2016-09-27       Impact factor: 4.566

Review 2.  Non-alcoholic fatty liver disease: an update on diagnosis.

Authors:  Dan L Dumitrascu; Manuela G Neuman
Journal:  Clujul Med       Date:  2018-04-25

3.  Lipocalin 2 induces neuroinflammation and blood-brain barrier dysfunction through liver-brain axis in murine model of nonalcoholic steatohepatitis.

Authors:  Ayan Mondal; Dipro Bose; Punnag Saha; Sutapa Sarkar; Ratanesh Seth; Diana Kimono; Muayad Albadrani; Mitzi Nagarkatti; Prakash Nagarkatti; Saurabh Chatterjee
Journal:  J Neuroinflammation       Date:  2020-07-04       Impact factor: 8.322

4.  Discovery, validation and sequencing of urinary peptides for diagnosis of liver fibrosis-A multicentre study.

Authors:  Ayman S Bannaga; Jochen Metzger; Ioannis Kyrou; Torsten Voigtländer; Thorsten Book; Jesus Melgarejo; Agnieszka Latosinska; Martin Pejchinovski; Jan A Staessen; Harald Mischak; Michael P Manns; Ramesh P Arasaradnam
Journal:  EBioMedicine       Date:  2020-11-05       Impact factor: 8.143

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.